BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SIRS-Lab GmbH Receives CE Approval for Sepsis Test "VYOO" and Unfolds Full Clinical Potential


12/3/2008 7:40:22 AM

JENA, Germany--(BUSINESS WIRE)--SIRS-Lab today announced that the EU regulatory authorities have granted the CE mark for VYOO, a molecular diagnostic test for pathogen detection in sepsis. With VYOO, clinicians can rapidly and reliably identify causative pathogens as well as important antibiotic resistance markers. Therefore VYOO allows for a customized anti-infective therapy in each patient within the critical hours of treatment. The CE mark will accelerate the implementation of VYOO into clinical routine throughout Europe.

Sepsis, a life-threatening systemic infection, is with more than 2 million cases per year the 2nd cause of death in hospitals after cardio-vascular diseases. SIRS-Lab, a leading molecular diagnostic company in the field of sepsis, has released VYOO in 2007. The cutting-edge pathogen detection test provides significant advantages over currently used methods in clinical practice.

In his comments on the CE approval, SIRS-Lab’s CEO PD Dr Stefan Russwurm states: “In important European clinical centers, for example in Paris or Basel, patients already benefit from the therapeutic advantages provided by VYOO. With the CE status, the full potential of this ground-breaking approach to sepsis diagnostics will be realized.”

For SIRS-Lab, the CE approval is an important milestone enabling the company to manufacture VYOO in accordance to ISO 13485 standards and sell it for routine In-vitro diagnostic use (IVD directive 98/79/EC).

For further information, please visit: www.sirs-lab.com

Press Room: http://www.sirs-lab.com/145-0-press-room.html

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5845077

Contact:

SIRS-Lab GmbH Axel Kunz, +49 3641 508 430 kunz@sirs-lab.com

Source: SIRS-Lab GmbH

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES